BrainStorm to Present at Cell & Gene Exchange Conference in Washington DC

HACKENSACK, N.J. and PETACH TIKVAH, Israel, May 22, 2017 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that the Company will present data from its Phase 2 clinical study of NurOwn® in amyotrophic lateral sclerosis (ALS) at the Inaugural “Cell & Gene Exchange” conference in Washington DC.  Dr. Ralph Kern, MD, Chief Operating Officer & Chief Medical Officer, will participate in a panel titled “Clinical updates: Promising cell and gene therapy programs,” followed by a company update delivered by Chaim Lebovits, Chief Executive Officer.